RET-selective inhibitors such as selpercatinib have demonstrated durable responses in solid tumours bearing RET rearrangements; pre-screening of relapsed osteosarcoma for rarer NTRK or RET fusions therefore represents a rational enrichment strategy for precision trials that marry cytostatic and immunomodulatory endpoints. The gene discussed is RET; the disease is osteosarcoma.